NewsBenzingaNuvectis Pharma公布其NXP200 1b期试验数据:基于神经肿瘤学反应评估标准2.0的客观缓解率为40%;深度缓解率为87.5% Nuvectis Pharma公布其NXP200 1b期试验数据:基于神经肿瘤学反应评估标准2.0的客观缓解率为40%;深度缓解率为87.5% Benzinga 2026.10.26 12:34 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT